País: Canadà
Idioma: anglès
Font: Health Canada
MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP A; MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP C; MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP Y; MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP W-135
SANOFI PASTEUR LIMITED
J07AH04
MENINGOCOCCUS, A, C, Y, W-135, TETRAVAL. PURIFIED POLYSACC. ANTIGEN
50MCG; 50MCG; 50MCG; 50MCG
KIT
MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP A 50MCG; MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP C 50MCG; MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP Y 50MCG; MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP W-135 50MCG
SUBCUTANEOUS
0.5ML
Schedule D
VACCINES
Active ingredient group (AIG) number: 0440084002; AHFS:
CANCELLED POST MARKET
2017-04-05
SANOFI PASTEUR SECTION 1.3.1 PRODUCT MONOGRAPH 276 – MENOMUNE ® - A/C/Y/W-135 Page 1 of 29 PRODUCT MONOGRAPH MENOMUNE ® - A/C/Y/W-135 Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined Powder for Solution Active Immunizing Agent for the Prevention of Meningococcal Meningitis ATC Code: J07AH Manufactured by: SANOFI PASTEUR INC. Swiftwater, PA 18370 USA Distributed by: SANOFI PASTEUR LIMITED Toronto, Ontario, Canada CONTROL NO.: 151001 DATE OF APPROVAL: JULY 30, 2013 SANOFI PASTEUR SECTION 1.3.1 PRODUCT MONOGRAPH 276 – MENOMUNE ® - A/C/Y/W-135 Page 2 of 29 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................... 4 SUMMARY PRODUCT INFORMATION .................................................................................. 4 DESCRIPTION ............................................................................................................................... 4 INDICATIONS AND CLINICAL USE ........................................................................................ 4 CONTRAINDICATIONS ............................................................................................................... 5 WARNINGS AND PRECAUTIONS ............................................................................................. 5 Immune 6 Peri-Operative Considerations........................................................................................................... 6 Special Populations ........................................................................................................................... 7 Pregnant Women ............................................................................................................................... 7 Nursing Women................................................................................................................................. 7 Pediatrics 7 ADVERSE REACTIONS ................................................................................................ Llegiu el document complet